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Here, we have examined the expression of matrix metal-
loproteinase-19 (MMP-19) in human cutaneous wounds
and by human skin ¢broblasts in culture. Expression of
MMP-19 was detected by immunohistochemistry in ¢-
broblasts, capillary endothelial cells, and macrophages
in the dermal layer of large granulating wounds, as well
as in chronic venous and decubitus ulcers. MMP-19
mRNA expression and pro-MMP-19 production by der-
mal ¢broblasts in culture was potently enhanced by tu-
mor necrosis factor-a (TNF-a). Induction of MMP-19
expression by TNF-a was prevented partially by block-
ing the activation of extracellular signal-regulated kinase
(ERK)-1/2 by PD98059 and p38 activity by SB203580.
Activation of ERK1/2 by adenovirus-mediated delivery
of constitutively active MAPK/ERK kinase 1 resulted in
the induction of MMP-19 expression. Activation of p38
alone by adenovirally delivered constitutively active
MAPK kinase 3b (MKK3b) and MKK6b also enhanced
MMP-19 production, and the most potent induction of
MMP-19 expression was noted when ERK1/2 was acti-
vated in combination with p38. Activation of c-Jun N-
terminal kinase (JNK). Abundant pro-MMP-19 produc-
tion by ¢broblasts was associated with proteolytic pro-
cessing of secreted pro-MMP-19. These results suggest a
role of MMP-19 in cutaneous wound repair and identify
three distinct signaling pathways, which coordinately
mediate induction of MMP-19 expression in ¢broblasts:
mitogen-activated ERK1/2 pathway and stress-activated
JNK and p38 pathways, of which control proteolytic ac-
tivity of dermal ¢broblasts. Key word: mitogen-activated
protein kinase. J Invest Dermatol 121:997 ^1004, 2003
M
atrix metalloproteinases (MMP) are a family of
structurally related zinc-dependent neutral en-
dopeptidases collectively capable of degrading
essentially all components of the extracellular
matrix (ECM) (see Nagase andWoessner, 1999;
Johansson et al, 2000a). At present, 24 human members of MMP
gene family have been identi¢ed, and they are often classi¢ed
into subgroups of collagenases, gelatinases, stromelysins, mem-
brane-type MMP, and other MMPs based on their structure and
substrate speci¢city (Nagase andWoessner, 1999). There is consid-
erable amount of evidence that MMPs play an important role in
connective tissue remodeling in physiologic situations including
developmental tissue morphogenesis, tissue repair, and angiogen-
esis. In addition, MMPs also regulate cellular growth factor re-
sponse and in£ammatory reaction by cleavage of growth factors,
cytokines, chemokines, and their receptors (Sternlicht and Werb
2001). MMPs also play an important role in destruction of
normal tissue architecture, e.g., in rheumatoid arthritis,
osteoarthritis, autoimmune blistering skin disorders, cutaneous
photoaging, and tumor invasion and metastasis (Johansson et al,
2000a).
Human MMP-19 cDNA was initially cloned from liver and
mammary gland and was also identi¢ed as an autoantigen in in-
£amed rheumatoid synovium (Cossins et al, 1996; Pends et al, 1997;
Sedlacek et al, 1998). The catalytic domain of MMP-19 hydrolyzes
type IVcollagen, laminin, nidogen, large tenascin-C, ¢bronectin,
type I gelatin, aggrecan, and cartilage oligomeric matrix protein,
but not triple-helical type I collagen (Stracke et al, 2000a, b). The
activity of MMP-19 catalytic domain is inhibited by tissue inhi-
bitor of metalloproteinases-2 (TIMP-2), TIMP-3, and TIMP-4
and less e⁄ciently by TIMP-1 (Stracke et al, 2000b). Latent
MMP-19 is activated by autoproteolysis, and in contrast to several
other MMPs, MMP-19 is not known to activate any other latent
MMPs (Stracke et al, 2000b). Expression of MMP-19 has been
detected in injured and in£amed synovium, especially in en-
dothelial cells of synovial capillaries, suggesting a role for
MMP-19 in angiogenesis (Kolb et al, 1999; Konttinen et al, 1999).
Expression of MMP-19 is also enhanced in blood mononuclear
cells of patients with multiple sclerosis (Ramanathan et al, 2001).
In myoepithelial cells and epidermal keratinocytes, the expression
of MMP-19 is lost upon malignant transformation (Djonov et al,
2001; Impola et al, 2003). In culture, MMP-19 is expressed by sev-
eral types of malignant and normal cells, including epidermal
keratinocytes and dermal ¢broblasts (Grant et al, 1999; Impola
et al, 2003).
In this study, we have examined the role and regulation of
MMP-19 in dermal wound repair in vivo and by human skin
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¢broblasts in culture. MMP-19 was noted in dermal ¢broblasts,
macrophages, and endothelial cells during normal cutaneous
wound repair and in chronic cutaneous ulcers.We also show, that
tumor necrosis factor-a (TNF-a) potently enhances MMP-19 ex-
pression and that this is mediated coordinately via extracellular
signal-regulated kinase (ERK)1/2 and p38 mitogen-activated
protein kinase (MAPK) signaling pathways. These results provide
evidence for the role of MMP-19 in remodeling of dermal ECM
during wound repair. In addition, our results identify two dis-
tinct mechanisms of inducing proteolytic capacity of dermal
¢broblasts: mitogen-responsive ERK1/2 pathway and stress-acti-
vated p38 MAPK, suggesting that both play a role in controlling
the MMP-19 expression and proteolytic phenotype of ¢broblasts,
e.g., during wound repair.
MATERIALS AND METHODS
Materials Human recombinant TNF-a and epidermal growth factor
(EGF), MAPK/ERK kinase 1/2 (MEK1/2) inhibitor PD98059 (20 -amino-
30 -methoxy£avone), and p38 inhibitor SB203580 ([4-(£uorophenyl)-2-(4-
methylsul¢nylphenyl)-5-(4-pyridyl)1H-imidazole]) were obtained from
Calbiochem (San Diego, CA). Human recombinant transforming growth
factor-b and platelet-derived growth factor-AAwere obtained from Sigma
Chemical Co. (St. Louis, MO). Human recombinant interleukin-1b (IL-
1b) was obtained from Roche Molecular Biochemicals (Mannheim,
Germany).
Wound tissues Human wound samples comprising the epithelial
wound edge and the corresponding part of nonre-epithelialized dermis
were collected from patients with chronic venous and decubitus ulcers
(n¼ 9), who underwent excision and grafting procedures at the Helsinki
University Central Hospital. In addition, biopsies from well-granulating
ulcers (n¼ 5) (all less than 2 months old) that required skin grafting
because of their large size were also examined. The procedures were
approved by the local Ethical Committee. Informed consent was obtained
from each patient prior to the biopsy of wounds.
Immunohistochemistry Immunostainings were performed on
formalin-¢xed para⁄n-embedded tissue sections using the peroxidase^
antiperoxidase technique and diaminobenzidine as chromogenic substrate
(Saarialho-Kere et al, 1993). Rabbit polyclonal antiserum against human
MMP-19 (Research Diagnostics Inc., Flanders, NJ) was diluted 1:80 and
reacted overnight at 41C. On serial sections activated ¢broblasts were
stained with a monoclonal antibody to the N-terminus of the type I
procollagen (PC-I) molecule (1:500; MAB 1912; Chemicon, Temecula,
CA) (Vaalamo et al, 1997) and tissue macrophages with CD-68 (KP-1,
1:300, M814; Dako, Carpinteria, CA). Harris hematoxylin was used as
counterstain.
Cell cultures Normal human skin ¢broblast cultures were established
from punch biopsy obtained from a voluntary healthy male donor (age
23) and maintained in Dulbecco’s modi¢ed Eagle’s medium (DMEM)
supplemented with 10% fetal calf serum (FCS), 2 mM glutamine, 100 IU
per mL penicillin G, and 100 mg per mL of streptomycin. For experiments
with growth factors and cytokines, ¢broblasts were maintained in culture
medium supplemented with 0.5% FCS for 18 h, growth factors and
cytokines were then added, and the incubations were continued for
indicated periods of time. In experiments involving MAPK inhibitors,
these were added 1 h before growth factors or cytokines.
RNA analysis Total cellular RNA was isolated from cells using
the single-step method (Chomczynski and Sacchi, 1987). Northern
blot hybridizations were performed as described previously (Reunanen
et al, 1998) using a 1.5-kb cDNA for MMP-19 (Pendas et al, 1997). The
32P-cDNA^mRNA hybrids were visualized by autoradiography and
quantitated by scanning densitometry, and MMP-19 mRNA levels were
corrected for the levels of 18S rRNA in the same samples.
Assay of MMP-19 and TIMP-2 production Equal aliquots of the
conditioned medium of ¢broblasts were analyzed for the amount of
MMP-19 by western blotting, as described previously (Reunanen et al,
1998) using mouse monoclonal antibody against human MMP-19 (1:500)
(Pendas et al, 1997) or polyclonal rabbit antiserum against TIMP-2 (1:1000)
(Chemicon International Inc., Temecula, CA). For TIMP-2 western blot,
samples were reduced with 5% mercaptoethanol before electrophoretic
fractionation. Speci¢c binding of antibodies was detected with peroxidase-
conjugated secondary antibodies and visualized by enhanced chemi-
luminescence (ECL) (Amersham Corp., UK). The levels of immuno-
reactive MMP-19 were quantitated by densitometric scanning of the
X-ray ¢lms.
Assay of MAPK activation The levels of activated ERK1/2, c-Jun N-
terminal kinase (JNK), and p38 were determined by western blot analysis
using antibodies speci¢c for phosphorylated, activated forms of the
corresponding MAPKs (Cell Signaling Technology, Beverly, MA).
Fibroblasts were maintained in DMEM with 0.5% FCS for 18 h,
incubated with TNF-a for di¡erent periods of time, and then lyzed in 100
mL of Laemmli sample bu¡er. The samples were sonicated, fractionated by
10% SDS^PAGE, and transferred to Hybond ECL membrane (Amersham
Corp., UK). Western blotting was performed as described previously
(Reunanen et al, 1998), with phospho-speci¢c antibodies in dilution 1:1000.
As control, the levels of total p38 were determined in the same samples
using a speci¢c antibody (Cell Signaling Technology). Binding of
primary antibodies was detected with peroxidase-conjugated secondary
antibodies and visualized by ECL.
Infection of ¢broblasts with recombinant adenoviruses Recombi-
nant replication-de¢cient adenovirus RAdlacZ (RAd35) (Wilkinson
and Akrigg, 1992), which contains the Escherichia coli b-galacto-
sidase (lacZ) gene under the control of CMV IE promoter, and empty
adenovirus RAd66 (Wilkinson and Akrigg, 1992) were kindly provided
by G.W.G. Wilkinson (University of Cardi¡, Wales, UK). Adenovirus
containing the coding regions of mutated, constitutively active human
MEK1 (RAdMEK1ca) (Foschi et al, 1997) was kindly provided by
M. Foschi (University of Florence, Italy). Adenoviruses for consti-
tutively active MAPK kinase 7 (MKK7; RAdMKK7D) (Wang et al,
1998b), MKK3b (RAdMKK3bE) (Wang et al, 1998a), and MKK6b
(RAdMKK6bE) (Wang et al, 1998a) genes driven by CMV IE promoter
were provided by J. Han (Scripps Institute, La Jolla, CA). In experiments,
5105 ¢broblasts in suspension were infected as previously described with
recombinant adenoviruses at a multiplicity of infection of 500, which gives
100% transduction e⁄ciency (Reunanen et al, 2000), plated, and incubated
for 18 h. Culture medium (DMEM with 1% FCS) was changed, and the
cultures incubated for 24 h. Aliquots of conditioned medium were
analyzed for the levels of MMP-19 and TIMP-2, as described above. Cell
layers were harvested and used for RNA extraction or for determination of
MAPK activation.
RESULTS
Expression of MMP-19 by ¢broblasts, endothelial cells,
and macrophages in cutaneous wounds MMP-19 is a re-
cently discovered MMP that cleaves various ECM components
including basement membrane constituents and is expressed by
a wide array of malignant and normal cells, including human
skin ¢broblasts in culture (Grant et al, 1999). To examine the
possible role and regulation of MMP-19 in cutaneous ECM
remodeling, we ¢rst performed immunostainings on samples
from ¢ve human normally healing cutaneous wounds and nine
chronic dermal ulcers. Expression of immunoreactive MMP-19
was detected in ¢broblast-like cells in the wound stroma of well
granulating wounds (Fig 1A). MMP-19 expression was also
detected in chronic venous and decubitus ulcers (Fig 1B).
Staining of parallel sections for type I procollagen (PC-I)
revealed, that MMP-19-positive cells embedded in dermal layer
were ¢broblasts (Fig 1C,D). Interestingly, ¢broblasts expressing
MMP-19 were often found in the vicinity of in£ammatory cells
(Fig 1A). MMP-19 expression was also detected in microvascular
endothelial cells and mononuclear cells devoid of type I
procollagen (Fig 1C,D). Furthermore, MMP-19 expression was
noted particularly at the surface of the wound bed, but also
deeper in the dermis, in CD-68-positive mononuclear cells
representing macrophages (Fig 1E,F).
Induction of ¢broblast MMP-19 expression by TNF-a To
examine the possible regulation of ¢broblast MMP-19 expre-
ssion by in£ammatory cell-derived factors, we treated normal
human skin ¢broblasts in culture with di¡erent in£ammatory
998 HIETA ETAL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
cell-derived growth factors, which play a role in cutaneous
wound repair. Treatment of cells with TNF-a and IL-1b for 24 h
enhanced the expression of MMP-19 mRNA (by 1.9- and 2.0-
fold, respectively), as detected by northern blot hybridizations
(Fig 2A). MMP-19 expression by dermal ¢broblasts was also
enhanced by transforming growth factor-b, epidermal growth
factor, and platelet-derived growth factor-AA, but slightly less
potently (1.7- to 1.8-fold) than with TNF-a and IL-1b (Fig 2A).
Because the most potent induction of MMP-19 expression in
dermal ¢broblasts was obtained with TNF-a, we examined the
molecular mechanism of this response in detail. As shown in Fig
2B, the production of pro-MMP-19 by dermal ¢broblasts was
potently enhanced by a 24-h incubation withTNF-a, whereas the
production of TIMP-2 was not altered byTNF-a treatment.
Induction of ¢broblast MMP-19 expression by TNF-a is
mediated by ERK1/2 and p38 MAPK Our recent obser-
vations indicate, that activation of ¢broblast collagenase-1
(MMP-1) expression by TNF-a is mediated by p38 MAPK
(Reunanen et al, 2002). In this study, we elucidated the speci¢c
roles of these MAPK cascades in the regulation of the expression
of MMP-19 by human skin ¢broblasts. Initially, the cells were
treated with TNF-a (20 ng/mL) for di¡erent periods of time
and the activation of ERK1/2, JNK, and p38 was determined by
western blot analysis using antibodies against activated forms of
these MAPKs. As shown in Fig 3A, exposure of ¢broblasts to
TNF-a resulted in rapid and transient activation of ERK1/2 and
JNK, detected at 15 and 30 min of incubation. Interestingly, p38
MAPK was also rapidly (15 min) activated by TNF-a, and the
activation was still detectable after 6 h (Fig 3A). The levels of
total p38 were not altered by TNF-a in the same samples. As
noted above, treatment of dermal ¢broblasts with TNF-a
resulted in potent enhancement of MMP-19 mRNA abundance
and this e¡ect was in part (by 43%) prevented by MEK1/2
inhibitor PD98059 (20 ng/mL) (Fig 3B,C). In addition, TNF-a-
elicited induction of MMP-19 mRNA levels was in part (by
35%) prevented by p38 inhibitor SB203580 (10 mM) (Fig 3B,C).
These results provide evidence that both the ERK1/2 pathway
and the p38 MAPK cascade mediate enhancement of MMP-19
expression by TNF-a. Nevertheless, ¢broblasts treated with
Figure1. MMP-19 is expressed by ¢broblasts, endothelial cells, and macrophages in cutaneous wounds. Human skin samples were obtained from
chronic venous and decubitus ulcers (n¼ 9) and from clinically well granulating ulcers (less than 2 months old) (n¼ 5). Immunostainings were performed
on formalin-¢xed para⁄n-embedded tissue sections using the peroxidase^antiperoxidase technique and diaminobenzidine as chromogenic substrate. MMP-
19 expression was detected with rabbit polyclonal antiserum against human MMP-19. Activated ¢broblasts were stained with a monoclonal antibody to the
N-terminus of the type I procollagen (PC-I) molecule and macrophages with a monoclonal antibody against CD-68. Harris hematoxylin was used as
counterstain. (A) MMP-19-positive ¢broblasts in the wound stroma of a well-granulating ulcer containing in£ammatory cells. (B) A chronic venous ulcer
with ¢broblasts stained for MMP-19 protein. (C) Staining for MMP-19 in another chronic venous ulcer with positive ¢broblasts and endothelial cells. (D)
Staining for PC-I in a serial section. Arrows, corresponding MMP-19- and PC-I-positive ¢broblasts; arrowhead, a MMP-19-positive and PC-I-negative
mononuclear cell. (E) A 1-month-old well granulating ulcer stained for MMP-19. (F) Staining for CD-68 in a serial section to (E). Arrows, corresponding
MMP-19- and CD-68-positive macrophages; asterisks, corresponding regions. Bars, 24 mm.
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TNF-a expressed MMP-19 mRNAwhen both ERK1/2 and p38
pathways were blocked by PD98059 and SB203580, respectively
(Fig 3B,C), indicating involvement of other TNF-a-activated
signaling pathways, e.g., JNK, which could not be examined in
this context by a chemical inhibitor.
Activation of ERK1/2 and p38 results in induction of MMP-
19 expression by dermal ¢broblasts To directly examine the
role of ERK1/2, JNK, and p38 MAPK cascades in the regulation
of the expression of the endogenous MMP-19 gene, we utilized
adenovirus-mediated gene delivery of constitutively active
MEK1, MKK7, MKK3b, and MKK6b to ¢broblasts. Our
previous observations show that transduction of ¢broblasts with
recombinant adenovirus RAdMEK1ca harboring constitutively
active mutant of MEK1 resulted in marked activation of ERK1/
2, but not p38 or JNK (Ravanti et al, 1999; Reunanen et al, 2000,
2002). Infection of ¢broblasts with adenovirus RAdMKK7D
coding for constitutively active MKK7 speci¢cally activates JNK
(Reunanen et al, 2002). In addition, infection of cells with
adenoviruses for constitutively active MKK3b (RAdMKK3bE)
or MKK6b (RAdMKK6bE) alone or in combination results in
activation of p38, but not ERK1/2 or JNK (Ravanti et al, 1999;
Reunanen et al, 2000, 2002). As shown in Fig 4A,B, activation
of ERK1/2 by RAdMEK1ca resulted in induction of MMP-19
mRNA abundance in dermal ¢broblasts and this e¡ect was
augmented by simultaneous activation of p38 by adenoviral
delivery of constitutively active MKK3b and MKK6b.
Interestingly, infection of cells with RAdMKK6bE alone also
potently upregulated MMP-19 mRNA, whereas the e¡ect of
RAdMKK3bE was less potent (Fig 4A,B). Infection of cells
with the control adenovirus RAdlacZ had no e¡ect on MMP-19
mRNA levels in ¢broblasts (Fig 4A,B). Adenoviral delivery of
constitutively active MKK7D alone had no e¡ect on MMP-19
mRNA abundance, but it markedly (twofold) augmented the
upregulatory e¡ect of constitutively active MEK1 on MMP-19
mRNA levels (Fig 4C).
Transduction of ¢broblasts with RAdMEK1ca also resulted in
marked induction of proMMP-19 production, and this e¡ect was
potently inhibited by MEK1/2 inhibitor PD98059 (Fig 4D,E). The
stimulatory e¡ect of RAdMEK1ca on proMMP-19 production
was augmented by simultaneous expression of constitutively
Figure 3. Induction of ¢broblast MMP-19 expression by TNF-a is
mediated by ERK1/2 and p38 MAPK. (A) Human skin ¢broblasts were
treated with TNF-a (20 ng/mL) for di¡erent periods of time, as indicated.
The levels of activated ERK1/2 (p-ERK1/2), JNK (p-JNK), and p38
(p-p38) were determined by western blot analysis using phosphospeci¢c
antibodies for the corresponding MAP kinases.The levels of total p38 were
determined in the same samples by western blot analysis using a speci¢c
antibody. (B) Human skin ¢broblasts were treated for 24 h with TNF-a
(20 ng/mL) alone or in combination with PD98059, a speci¢c inhibitor of
ERK1/2 kinases MEK1/2, or with SB203580, a selective inhibitor of p38
MAPK, added 1 h before TNF-a in concentrations (mM) indicated. Ali-
quots (15 mg) of total RNAwere analyzed for levels of MMP-19 by north-
ern blot hybridization. 18S rRNA was visualized by ethidium bromide
staining. (C) Densitometric quantitation of MMP-19 mRNA levels in
northern blot hybridizations corrected for 18S rRNA levels. The values
are shown relative to levels in untreated control cultures (1.0). The values
represent means of two independent experiments.
Figure 2. Fibroblast MMP-19 expression is induced by TNF-a. (A)
Human skin ¢broblasts in culture were treated for 24 h with IL-1b (10
U/mL), TNF-a (20 ng/mL), transforming growth factor-b1 (TGF-b1)
(5 ng/mL), epidermal growth factor (EGF) (25 ng/mL), and platelet-de-
rived growth factor-AA (PDGF-AA) (20 ng/mL). Aliquots (15 mg) of total
RNAwere analyzed for levels of MMP-19 mRNA by northern blot hybri-
dizations. 18S rRNAwas visualized by ethidium bromide staining. (B) Hu-
man skin ¢broblasts were treated with TNF-a (20 ng/mL) and incubated
for 24 h. The levels of proMMP-19 and TIMP-2 in the conditioned med-
ium of the cells were determined by western blot analysis.
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active MKK7 and the most abundant production of proMMP-19
was noted when ERK1/2 was activated in combination with p38
by constitutively active MKK3b and MKK6b (Fig 4D,E).
Production of pro-MMP-19 was also induced by RAdMKK3bE
and RAdMKK6bE, and this e¡ect was entirely inhibited by p38
inhibitor SB203580 (Fig 4D,E). Interestingly, in cells infected
with RAdMEK1ca in combination with RAdMKK7D,
RAdMKK3bE, or RAdMKK6bE, abundant pro-MMP-19
Figure 4. Activation of ERK1/2 and p38 results in induction of MMP-19 expression by ¢broblasts. (A) Human skin ¢broblasts (5105) were
transduced with replication-de¢cient empty control adenovirus (RAd66) or with adenoviruses coding for constitutively active forms of MEK1 (RAd-
MEK1ca), MKK3b (RAdMKK3bE), or MKK6b (RAdMKK6bE), as indicated at a multiplicity of infection of 500 and incubated for 18 h in DMEM
supplemented with 1% FCS. Medium was then changed, the incubations were continued for 24 h, and the cells were harvested. Aliquots (10 mg) of total
RNA were analyzed for the levels of MMP-19 mRNA with northern blot hybridization. 18S rRNA was visualized by ethidium bromide staining. (B)
Densitometric quantitation of MMP-19 mRNA levels in northern blot hybridizations corrected for 18S rRNA levels and shown relative to levels in un-
treated control cultures (1.0). The values represent means of two independent experiments. (C) Human skin ¢broblasts (5105) were transduced with
replication-de¢cient empty control adenovirus (RAd66) or with adenoviruses RAdMEK1ca and RAdMKK7D coding for constitutively active MKK7, as
in (A). Aliquots 12 mg of total RNA were analyzed for the levels of MMP-19 mRNA with northern blot hybridization. 18S rRNA was visualized by
ethidium bromide staining. Densitometric quantitation of MMP-19 mRNA levels corrected for 18S rRNA levels in the same samples are shown below
the panels relative to levels in untreated control cultures (1.0). (D) Human skin ¢broblasts were infected with empty control adenovirus (RAd66) or with
adenoviruses RAdMEK1ca and RAdMKK7D and with adenoviruses harboring constitutively active MKK3b (RAdMKK3bE) and MKK6b
(RAdMKK6bE), as indicated at a multiplicity of infection of 500, and incubated for 18 h in DMEM supplemented with 1% FCS. MEK1/2 inhibitor
PD98059 (40 mM) and p38 inhibitor SB203580 (20 mM) were added to cultures indicated at the time of infection. After 18 h, medium was changed, fresh
PD98059 and SB203580 were added, and incubations were continued for 24 h. The levels of MMP-19 and TIMP-2 in the conditioned medium of the cells
were determined by western blot analysis. Migration positions of molecular weight markers are shown on the right. (E) Densitometric quantitation of
MMP-19 mRNA levels in northern blot hybridizations corrected for 18S rRNA levels. The values are shown relative to levels in untreated control cultures
(1.0). The values represent means of two independent experiments.
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production was associated with proteolytic processing of pro-
MMP-19 with an estimated molecular weight of 58 kDa
to active MMP-19, noted as the appearance of approximately
10-kDa smaller immunoreactive protein in western blot (Fig
4D). Infection of ¢broblasts with the empty control adenovirus
RAd66 had no e¡ect on the production of MMP-19 (Fig
4D,E). In the same cells, the production of TIMP-2 was not
induced in parallel with MMP-19 (Fig 4D).
DISCUSSION
In this study, we have examined the role and regulation of MMP-
19, a newly discovered MMP with catalytic activity against
several ECM components including constituents of basement
membrane, in dermal ¢broblasts in vivo and in culture. Our re-
sults show that MMP-19 is expressed by ¢broblasts in the dermal
layer of normally healing and chronic cutaneous wounds. The
expression of MMP-19 was also detected in capillary endothelial
cells in the wounds. Furthermore, expression of MMP-19 was de-
tected in mononuclear in£ammatory cells negative for procolla-
gen I and positive for CD68 and therefore representing
macrophages.These results are in accordance with previous obser-
vations showing expression of MMP-19 on the surface of blood
mononuclear cells (Sedlacek et al, 1998) and myeloid cells
(Mauch et al, 2002). Our results also show that the expression of
MMP-19 in dermal ¢broblasts is potently enhanced by TNF-a,
suggesting a role for MMP-19 in degradation of dermal ECM in
in£ammatory conditions. This conclusion is supported by our
¢nding that MMP-19 is produced in wound stroma by ¢broblasts
often located in areas in¢ltrated by in£ammatory cells. Further
evidence for the role for MMP-19 in wound repair is also
provided by our observations that the expression of MMP-19 by
¢broblasts in healthy intact skin is very low (Impola et al, 2003).
We also dissected the role of three distinct MAPK signaling
pathways, ERK1/2, JNK, and p38, in the regulation of MMP-19
expression in normal human skin ¢broblasts in culture.We show
that treatment with TNF-a simultaneously activates ERK1/2,
JNK, and p38 in ¢broblasts and that these pathways play a dis-
tinct role in the induction of MMP-19 expression. The up-regu-
lation of MMP-19 expression by TNF-a was mediated by
coordinate activation of ERK1/2 and p38. Nevertheless, blocking
both ERK1/2 and p38 pathways by chemical inhibitors did not
block the e¡ect of TNF-a on MMP-19 mRNA levels, indicating
that other TNF-a-activated signaling pathways, e.g., JNK or NF-
kB, may be involved. Interestingly, we have recently noted that
TNF-a also enhances expression of MMP-19 by epidermal kera-
tinocytes, suggesting that this proin£ammatory cytokine plays an
important role in up-regulation of MMP-19 expression both in
the dermal and in the epidermal compartment during wound re-
pair (Impola et al, 2003).
We also utilized adenovirus-mediated gene delivery of consti-
tutively active MEK1, MKK7, MKK3b, and MKK6b to examine
the e¡ect of the activation of corresponding endogenous MAPKs
on the expression of MMP-19 in normal human skin ¢broblasts.
Our results showed that activation of ERK1/2 by constitutively
active MEK1 resulted in marked induction of MMP-19 expres-
sion, the most abundant expression noted when ERK1/2 was ac-
tivated in combination with JNK or p38. Interestingly, activation
of p38 alone by adenovirus-mediated delivery of constitutively
active MKK3b and MKK6b also resulted in induction of the ex-
pression of MMP-19, whereas speci¢c activation of JNK alone by
constitutively active MKK7 was not su⁄cient to induce expres-
sion of MMP-19. Activation of ERK1/2 by constitutively active
MEK1 and p38 MAPK by MKK3b and MKK6b also resulted in
marked induction of pro-MMP-19 production, and the most po-
tent induction was noted when ERK1/2 was activated in combi-
nation with JNK and p38. Interestingly, abundant pro-MMP-19
production by ¢broblasts also resulted in proteolytic processing
of pro-MMP-19, most likely owing to autoproteolytic activation
(Stracke et al, 2000b). Taken together, these results indicate that
both ERK1/2 and p38 signaling pathways play an important role
in regulating the production and activation of proMMP-19 by
¢broblasts.
MAPK play an important role in regulating cell growth, dif-
ferentiation, survival, and death (Garrington and Johnson, 1999;
Westermarck and Khri, 1999). To date, three mammalian
MAPK pathways have been characterized in detail: mitogen-
activated ERK1/2 pathway (Raf-MEK1/2-ERK1/2), JNK
(MEKK1-4-MKK4/7-JNK1-3), and p38 (MAPK kinase ki-
nase-MKK3/6-p38a/b) pathways, activated by in£ammatory
cytokines and cellular stress (see Garrington and Johnson, 1999;
Westermarck and Kahari, 1999). Activation and nuclear transloca-
tion of MAPKs results in phosphorylation and activation of their
downstream e¡ectors, nuclear protein kinases, e.g., MAPK-
activated protein kinases-1, -2, and -3 or transcription factors,
e.g., Elk-1, c-Jun, activating transcription factor 2, and cyclic
AMP response element-binding protein, which in turn regulate,
e.g., expression of the components of AP-1 complex (see
Garrington and Johnson, 1999; Westermarck and Kahari, 1999).
Recent observations have provided evidence that ERK1/2,
JNK, and p38 MAPK regulate the proteolytic capacity of
¢broblasts and squamous carcinoma cells by mediating the acti-
vation of MMP-1, stromelysin-1 (MMP-3), gelatinase-B (MMP-
9), and collagenase-3 (MMP-13) expression (Gum et al, 1997;
Ridley et al, 1997; Reunanen et al, 1998, 2002; Simon et al,
1998; Ravanti et al, 1999; Johansson et al, 2000b; Westermarck
et al, 2001).
Constant activation of ERK1/2 by active mutants of Raf-1 or
MEK1 results in transformation of ¢broblasts (Cowley et al, 1994;
Janulis et al, 1999; Mansour et al, 1994). Furthermore, activation of
ERK1/2 pathway has been documented in renal and breast
carcinomas in vivo (Oka et al, 1995; Sivaraman et al, 1997).The con-
sequences of ERK1/2 activation are cell-speci¢c, because activa-
tion of ERK1/2 cascade results in growth arrest in small-cell
lung carcinoma cells (Ravi et al, 1998) and suppresses MMP-13
expression by SCC cells (Ala-aho et al, 2000). Our recent observa-
tions showed that ERK1/2 activity increases the expression of
MMP-1 and MMP-3 in ¢broblasts (Reunanen et al, 2002). Our
results here show that MMP-19 production by ¢broblasts expres-
sing constitutively active MEK1 is further enhanced, when con-
stant activation of ERK1/2 is superimposed on persistent
activation of JNK or p38. This phenomenon may play an impor-
tant role in wound repair, in which dermal ¢broblasts are ex-
posed to cytokines produced by in£ammatory cells, resulting in
coordinate activation of ERK1/2, JNK, and p38.
Our recent observations show that activation of p38 MAPK by
constitutively active MKK3b and MKK6b has no marked e¡ect
on human MMP-1 promoter activity, but that activation of p38a
results in marked stabilization of both MMP-1 and MMP-3
mRNAs (Westermarck et al, 2001; Reunanen et al, 2002).We have
also recently shown that p38a mediates activation of protein
phosphatases 1 and 2 A resulting in inhibition of ERK1, 2 cascade
at the level of MEK1,2 resulting in suppression of MMP-1 pro-
moter activity (Westermarck et al, 2001). The results presented
here show that activation of p38 also induces expression of
MMP-19 by dermal ¢broblasts. It is therefore possible that activa-
tion of p38a also enhances the expression of MMP-19 expression
via mRNA stability.
Controlled turnover of collagenous ECM and basement mem-
branes is an important feature in connective tissue remodeling in
physiologic situations, such as tissue repair and angiogenesis, as
well as in pathologic conditions, including rheumatoid arthritis,
chronic ulcers, and tumor invasion (Johansson et al, 2000a). The
ability to degrade type I collagen is essential for migration of epi-
dermal keratinocytes (Pilcher et al, 1997). In addition, cleavage of
the surrounding collagenous ECM by ¢broblasts alters their cell^
matrix interactions and facilitates their migration capacity (Mes-
sent et al, 1998). It has also been suggested that imbalance in the
production of MMP and TIMP-2 may inhibit keratinocyte mi-
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gration and lack of TIMP-1 and TIMP-3 expression by proliferat-
ing keratinocytes may compromise stability of basement mem-
brane in chronic ulcers (Vaalamo et al, 1999). In this context, it is
interesting to note that MMP-19 has been suggested to play a role
in migration of myeloid cells, which express MMP-19 on their
surface (Mauch et al, 2002). The results of this study do not allow
conclusions to be made on the role of MMP-19 expression in the
¢broblast phenotype during wound repair. Nevertheless, our re-
cent observation show that MMP-19 is not expressed by migrat-
ing keratinocytes, but in proliferating keratinocytes during
cutaneous wound repair, indicating that MMP-19 expression is
not necessarily associated with cell migration (Impola et al,
2003). This notion is further supported by our recent observation
that MMP-19 is expressed by proliferating keratinocytes in psor-
iatic epidermis (Suomela et al, 2003).
Our results identify ERK1/2 and p38 as two distinct MAPK
pathways independently mediating the activation of the expres-
sion of the basement membrane degrading MMP-19 in ¢bro-
blasts. Constant activation of ERK1/2 in dermal ¢broblasts also
results in marked suppression in their production of type I col-
lagen and collagen ¢bril-associated proteoglycan, decorin (Laine
et al, 2000; Reunanen et al, 2000), and enhances the expression of
ECM degrading MMP-1 (collagenase-1) and MMP-3 (stromely-
sin-1) (Reunanen et al, 2002). Together these results provide evi-
dence that ERK1/2 serves as an important molecular switch, the
activation of which alters the ECM productive phenotype of nor-
mal ¢broblasts to proteolytic phenotype characterized by pro-
duction of ECM cleaving MMPs and suppression of ECM
deposition. Nevertheless, in the presence of the activation
of stress-activated JNK and p38 MAPK, ERK1/2 activity is not
essential for induction of ¢broblast MMP-19 mRNA and protein
by TNF-a. Furthermore, activation of p38 is alone su⁄cient to
induce the expression of MMP-19 mRNA and protein. Never-
theless, our results clearly show that coordinate activation of
ERK1/2 in combination with JNK or p38 MAPK results in
most potent induction of MMP-19 expression and apparently
plays a crucial role in stimulation of the proteolytic capacity of
normal ¢broblasts in vivo, e.g., during wound repair and tumor
invasion.
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